FY2028 Earnings Estimate for TNXP Issued By Zacks Research

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) – Stock analysts at Zacks Research issued their FY2028 EPS estimates for shares of Tonix Pharmaceuticals in a note issued to investors on Monday, March 23rd. Zacks Research analyst D. Bautz expects that the company will earn $1.97 per share for the year. The consensus estimate for Tonix Pharmaceuticals’ current full-year earnings is ($1,762.50) per share.

A number of other equities research analysts have also recently issued reports on the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Tonix Pharmaceuticals in a research note on Wednesday, January 21st. Wall Street Zen raised shares of Tonix Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, January 17th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold”.

Tonix Pharmaceuticals Stock Performance

Shares of NASDAQ TNXP opened at $15.00 on Wednesday. The stock has a 50 day moving average price of $15.54 and a 200 day moving average price of $18.14. The stock has a market capitalization of $201.08 million, a PE ratio of -1.05 and a beta of 1.88. Tonix Pharmaceuticals has a 52 week low of $13.07 and a 52 week high of $69.97.

Tonix Pharmaceuticals (NASDAQ:TNXP) last announced its quarterly earnings data on Thursday, March 12th. The company reported ($3.98) earnings per share for the quarter, missing the consensus estimate of ($3.16) by ($0.82). Tonix Pharmaceuticals had a negative net margin of 946.22% and a negative return on equity of 60.15%. The company had revenue of $5.39 million during the quarter, compared to the consensus estimate of $2.97 million.

Insider Transactions at Tonix Pharmaceuticals

In other Tonix Pharmaceuticals news, CEO Seth Lederman acquired 15,000 shares of the business’s stock in a transaction dated Wednesday, March 18th. The stock was bought at an average cost of $14.89 per share, with a total value of $223,350.00. Following the completion of the transaction, the chief executive officer directly owned 15,001 shares in the company, valued at approximately $223,364.89. This represents a 1,500,000.00% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 0.03% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Nisa Investment Advisors LLC acquired a new position in shares of Tonix Pharmaceuticals in the third quarter valued at $358,000. Tower Research Capital LLC TRC raised its position in shares of Tonix Pharmaceuticals by 108.4% in the second quarter. Tower Research Capital LLC TRC now owns 7,172 shares of the company’s stock valued at $258,000 after purchasing an additional 3,731 shares during the period. BNP Paribas Financial Markets acquired a new stake in shares of Tonix Pharmaceuticals during the 2nd quarter worth about $65,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in shares of Tonix Pharmaceuticals during the 2nd quarter worth about $149,000. Finally, JT Stratford LLC bought a new stake in shares of Tonix Pharmaceuticals during the 2nd quarter worth about $232,000. 82.26% of the stock is owned by institutional investors and hedge funds.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals is a clinical-stage biotechnology company focused on developing therapeutics for central nervous system disorders, immunology and rare diseases. The company’s pipeline includes small-molecule and biologic product candidates designed to address conditions such as fibromyalgia, post-traumatic stress disorder (PTSD) and other chronic pain syndromes, as well as vaccines for potential viral and biothreat agents.

Among Tonix’s lead programs is TNX-102 SL, a sublingual formulation of cyclobenzaprine being evaluated for the treatment of fibromyalgia and PTSD.